文献速递肿瘤 PET/CT

18F-氟昔洛韦PET/CT显像结果对前列腺癌生化复发挽救性放疗后无失败生存的影响

Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy.
PubMed 文献 · Clin Nucl Med · 2023-02-08

本研究纳入79例前列腺癌生化复发患者,在挽救性放疗前行18F-氟昔洛韦PET/CT,排除4例盆腔外病变后分析75例,随访至48个月。PET/CT阳性者36个月和48个月无失败生存率分别为62.3%和59.4%,阴性者均为92.9%(P<0.001);盆腔淋巴结±瘤床摄取者无失败生存率低于仅瘤床摄取者。

要点

  • 80%(60/75)患者PET/CT阳性,其中56.7%仅瘤床摄取,43.3%盆腔淋巴结±瘤床摄取。
  • PET/CT阳性者36个月无失败生存率62.3% vs 阴性者92.9%(P<0.001)。
  • 盆腔淋巴结±瘤床摄取者48个月无失败生存率49.8% vs 仅瘤床摄取者65.6%(P=0.040)。

核心结论

  • 挽救性放疗前18F-氟昔洛韦PET/CT显像结果可预测根治性前列腺切除术后生化复发患者放疗后的无失败生存。
  • PET/CT阴性最预示失败风险较低,而存在盆腔淋巴结复发则预示挽救性放疗失败风险较高。

研究设计与样本

  • 79例前列腺癌患者在2/3期临床试验中于挽救性放疗前行18F-氟昔洛韦PET/CT,排除4例盆腔外病变后75例纳入分析,定期随访至48个月。
  • 治疗失败定义为挽救性放疗后血清前列腺特异性抗原水平较最低值升高≥0.2 ng/mL并经再次检测确认,或需全身治疗或临床进展。

主要发现

  • 80%(60/75)患者PET/CT阳性,其中56.7%(34/60)仅瘤床摄取,43.3%(26/60)盆腔淋巴结±瘤床摄取。
  • 挽救性放疗后36%(27/75)患者出现疾病失败。
  • PET/CT阳性 vs 阴性者无失败生存率:36个月62.3% vs 92.9%(P<0.001),48个月59.4% vs 92.9%(P<0.001)。
  • 盆腔淋巴结±瘤床摄取 vs 仅瘤床摄取者无失败生存率:36个月49.8% vs 70.7%(P=0.003),48个月49.8% vs 65.6%(P=0.040)。
  • PET/CT阴性或仅瘤床病变 vs 盆腔淋巴结±瘤床病变者无失败生存率:36个月78% vs 49.8%(P<0.001),48个月74.4% vs 49.8%(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to evaluate the impact of 18 F-fluciclovine PET/CT imaging on failure-free survival (FFS) post-salvage radiotherapy (SRT) for prostate cancer (PCa) recurrence. METHODS: Seventy-nine patients were recruited in a phase 2/3 clinical trial to undergo 18 F-fluciclovine PET/CT before SRT for PCa. Four patients with extrapelvic disease were excluded. All patients were followed up at regular intervals up to 48 months. Treatment failure was defined as a serum prostate-specific antigen level of ≥0.2 ng/mL above the nadir after SRT, confirmed with an additional measurement, requiring systemic treatment or clinical progression. Failure-free survival was computed and compared between patients grouped according to 18 F-fluciclovine PET/CT imaging findings. RESULTS: Eighty percent (60/75) of patients had a positive finding on 18 F-fluciclovine PET/CT, of which 56.7% (34/60) had prostate bed-only uptake, whereas 43.3% (26/60) had pelvic nodal ± bed uptake. Following SRT, disease failure was detected in 36% (27/75) of patients. There was a significant difference in FFS between patients who had a positive versus negative scan (62.3% vs 92.9% [ P < 0.001] at 36 months and 59.4% vs 92.9% [ P < 0.001] at 48 months). Similarly, there was a significant difference in FFS between patients with uptake in pelvic nodes ± bed versus prostate bed only at 36 months (49.8% vs 70.7%; P = 0.003) and at 48 months (49.8% vs 65.6%; P = 0.040). Failure-free survival was also significantly higher in patients with either negative PET/CT or prostate bed-only disease versus those with pelvic nodal ± prostate bed disease at 36 (78% vs 49.8%, P < 0.001) and 48 months (74.4% vs 49.8%, P < 0.001). CONCLUSIONS: Findings on pre-SRT 18 F-fluciclovine PET/CT imaging, even when acted upon to optimize the treatment decisions and treatment planning, are predictive of post-SRT FFS in men who experience PCa recurrence after radical prostatectomy. A negative 18 F-fluciclovine PET/CT is most predictive of a lower risk of failure, whereas the presence of pelvic nodal recurrence portends a higher risk of SRT failure.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lawal IO, Marcus C, Schuster DM, et al. Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy. Clin Nucl Med. 2023. PMID: 36754362. doi:10.1097/RLU.0000000000004590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。